[Press Release]PharmAbcine Announces Japan Patent Registration for PMC-403

29 Feb 2024
TitlePharmAbcine Announces Japan Patent Registration for PMC-403
CategoryPress Release

PharmAbcine Announces Japan Patent Registration for PMC-403

  • Registered patent based on the novel mechanism of PMC-403 in normalizing vessel leakage by TIE2 activation.
  • Currently undergoing Phase 1 clinical trial for patients with neovascular age-related macular degeneration, with therapeutic potential to expand in additional vessel-related diseases.

Daejeon, South Korea, February 29, 2024 /PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public company developing next generation therapeutics to treat medical unmet needs, announced today the registration of Japan patent for its candidate drug, PMC-403, marking the third patent registration following Russia and Singapore.

PMC-403 is a novel first-in-class therapeutic antibody candidate with a unique mechanism of activating TIE2 receptors in endothelial cells. PMC-403 normalizes pathological leaky blood vessels by activating TIE2 receptors in endothelial cells. Through TIE2 activation, PMC-403 inhibits VEGFR-2 phosphorylation and maintains intercellular adhesion factors, thereby inhibiting vascular leakage caused by neovascularization.

The registered patent pertains to PMC-403’s TIE2-binding antibody compositions. Patent registrations are currently underway in countries including the United States, Europe, China, and Korea. The Company anticipates that the registrations in Japan, Russia and Singapore will positively impact registrations in other countries.

A representative from PharmAbcine stated, "Through the ongoing clinical trial, we expect to strengthen the exclusive rights of PMC-403 in major countries." They added, "Along with patent acquisition, we are eager to maximize the therapeutic potential of PMC-403 in various vessel-related diseases such as cancer, age-related macular degeneration, diabetic retinopathy, kidney disease, and many others."

With a mechanism distinct from currently available therapies, PMC-403 is undergoing Phase 1 clinical trial targeting patients with neovascular age-related macular degeneration in Korea. The evaluation of efficacy and safety in the third dosing group (3mg) is ongoing, following confirmation of safety in the second dosing group (2mg). After this is complete, both the last single-dose group (4mg) and the first multiple-dose group (MAD 3mg) will proceed simultaneously.

About PharmAbcine Inc.

PharmAbcine is a clinical stage public company developing next generation IgG based therapeutics to treat cancer, neovascular eye diseases, and vascular related unmet needs.

The Company’s main pipeline include clinical assets olinvacimab, PMC-403, and PMC-309.

Olinvacimab, the Company’s lead asset, is ongoing a Phase II trial in combination with MSD’s pembrolizumab for mTNBC patients in Australia to reconfirm the encouraging result from Phase Ib olinvacimab plus pembrolizumab trial, delivering 50% ORR, 67% DCR, and clean safety profile.

PMC-403 is a novel TIE2-activating antibody that stabilizes dysfunctional leaky disorganized pathological vessels and can be used for vascular-related eye disease, including wet AMD (Age-related Macular Degeneration). PMC-403 is currently undergoing Phase I trial for neovascular AMD patients in Korea. PMC-403 is also being explored to expand into wider therapeutic areas related to pathological vessels including vessel-related rare diseases and non-rare diseases.

PMC-309, a novel anti-VISTA-antagonizing IgG in pan pH conditions, is an immune checkpoint regulator that targets MDSC (myeloid derived suppressor cells) and M2 macrophages which play pivotal role in maintaining immunosuppressive TME (Tumor Microenvironment). Currently, Phase I is ongoing at multi-centers in Australia and Phase Ib/II in combination with the PMC-309 + pembrolizumab combo will follow under the collaboration with MSD. 

PMC-005, is an anti-EGFRviii IgG that only binds to EGFRviii expressed on cancer cells and can be applied to various modalities including CAR-T, CAR-NK, CAR-Macrophage, T cell/NK cell engager, and Radio-Immunotherapy.

     2F, Research Building 2, 70,

     Yuseong-daero 1689 beon-gil,
     Yuseong-gu, Daejeon, 34047, Republic of Korea

     HQ +82-42-863-2017 

     R&D Center +82-42-861-2017

     Investor Relations +70-4294-6097 

     FAX +82-42-863-2080 

     COPYRIGHT BY PharmAbcine Inc.